Ovagen

Ovagen is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and leucine (Glu-Asp-Leu). Molecular formula C15H25N3O8, molecular weight 375.37 g/mol. The compound is indexed in PubChem under CID 444128. It belongs to the Khavinson Cytogen class developed at the St. Petersburg Institute of Bioregulation and Gerontology and is marketed as the synthetic counterpart to the liver Cytomax Svetinorm.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts from young animal tissues, containing heterogeneous mixtures of short peptides up to roughly 10 kDa. Cytogens are short synthetic peptides, typically two to four amino acids, designed to reproduce single defined sequences identified within the corresponding Cytomax. For the liver, the Cytomax is Svetinorm and the Cytogen is Ovagen. For the gastrointestinal tract, the same Ovagen sequence is used, since the Khavinson model treats hepatic and GI tissue as functionally linked through enterohepatic circulation and shared protein-synthesis demands.

The compound is described in Khavinson and coauthors' 2020 review in Biomedicines alongside other Cytogens. The full mechanistic framework treats Cytogens as gene-expression modulators that enter cells, reach the nucleus, and bind tissue-specific gene promoters. For Ovagen, the proposed target gene clusters include hepatocyte metabolic enzymes (cytochrome P450 family), glutathione S-transferases, albumin synthesis pathways, and gastrointestinal mucosal cell maintenance genes.

The Human Evidence

The compound-specific human evidence base for Ovagen consists of:

• Russian-institution clinical observation studies in elderly patients with hepatic dysfunction, including post-toxic and post-infectious liver conditions
• Reports of use in protocols for chemotherapy-induced gastrointestinal damage
• Use as part of broader Khavinson geroprotective protocols
• Animal studies in renal cell cultures undergoing senescence (used as a general model for cellular aging by the Khavinson group)

The cell-culture work on Ovagen modulating senescence markers has been more prominent in recent publications than the clinical data. Several Khavinson group papers describe gene-expression changes in cultured cells exposed to Ovagen, including modulation of expression of cytochrome P450 enzymes and antioxidant pathway components.

Independent confirmation of these effects by Western groups is limited. PubMed search for "Ovagen EDL" or "glutamyl-aspartyl-leucine" returns only Khavinson-affiliated publications and the PubChem chemical record. No registered ClinicalTrials.gov trial exists for Ovagen as of May 2026.

A reader evaluating Ovagen should weigh the following asymmetry. The Khavinson group's broader gene-expression peptide framework has accumulated peer-reviewed publications over decades and offers a coherent theoretical model. The compound-specific clinical data for Ovagen consists primarily of internal-network observational reports. Both the strength of the broader theoretical framework and the limited compound-specific human trial data should be acknowledged.

Regulatory and Legal Status

FDA. No approval. Not listed on bulk drug substances list. Importation permitted only as a research chemical labeled "not for human consumption."

EMA. No approval.

Russia. Registered as a biologically active dietary supplement. Sold in oral capsule format through the Khavinson distribution network.

WADA. Not on the 2026 Prohibited List.

The compound's synthetic-tripeptide nature places it in a different regulatory category from animal-derived Cytomaxes like Svetinorm. Synthetic short peptides with defined sequences can in principle be evaluated through standard pharmaceutical regulatory pathways, but Ovagen has not been submitted for FDA Investigational New Drug review.

The proposed mechanism follows the Khavinson short-peptide bioregulation model with liver and GI tissue specificity.

Cellular entry. The tripeptide is hypothesized to enter cells through peptide transporters (PEPT1 in the intestinal brush border, PEPT2 in renal and other tissues), reach the cytoplasm, and translocate to the nucleus. The small size (375 Da) facilitates passive diffusion through nuclear pores.

DNA binding. The Khavinson model proposes that short peptides bind double-stranded DNA in promoter regions of tissue-specific genes through sequence-selective recognition. For Ovagen, the Glu-Asp-Leu sequence is proposed to recognize particular motifs in liver and GI-cell gene promoters.

Gene-expression effects. Khavinson group publications describe Ovagen modulating expression of:

• Cytochrome P450 enzymes (CYP family) involved in Phase I detoxification
• Glutathione S-transferases involved in Phase II conjugation
• Albumin synthesis pathways
• Markers of hepatocyte regenerative capacity
• Gastrointestinal mucosal barrier proteins

The specific transcriptional readouts have been reported in cultured-cell experiments. Independent transcriptomic verification by Western groups in primary hepatocytes or in vivo human tissue is absent.

Pharmacokinetics. Oral tripeptides face significant gut hydrolysis. The Khavinson group has addressed this through two mechanistic claims: first, that a fraction of intact tripeptide is absorbed through PEPT1; second, that pharmacological effects can be initiated at the gut-mucosa interface and signaled systemically through neural and humoral pathways. Direct measurement of intact Ovagen in plasma after oral administration has not been published in peer-reviewed form.

Human pharmacokinetic data is not published in any English-language peer-reviewed journal. Plasma half-life, tissue distribution, and excretion patterns have not been characterized.

Reported effects come from Russian-institution clinical observation studies and from user reports in research-chemical communities outside Russia.

Russian-institution reports describe:

• Improvement in hepatic enzyme parameters (ALT, AST normalization) in elderly patients with mild hepatic dysfunction
• Symptom improvement in patients recovering from toxic hepatitis
• Adjunct effects in chemotherapy-induced gastrointestinal mucositis
• Improvement in markers of general hepatic regenerative capacity
• Anti-fibrotic effects in animal models of liver injury

Research-chemical user reports include:

• Subjective improvement in digestive comfort
• Reduced post-meal heaviness in users with self-reported sluggish digestion
• Improvement in markers of liver enzyme panels on routine bloodwork (uncontrolled, unverified)

None of these effects has been quantified in a placebo-controlled trial published in an English-language indexed journal. The Russian institutional reports are non-blinded and produced by the developer network. User reports are anecdotal and not verified for vial identity, dose accuracy, or co-intervention.

The honest framing: Ovagen has a plausible mechanism within the Khavinson bioregulator framework, internal Russian network reports of clinical effects, and no independent Western RCT evidence. Claims about hepatic or GI benefits should be treated as hypothesis-supported rather than evidence-based.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Ovagen.

The Russian retail product is dosed as oral capsules, typically 1 to 2 capsules once or twice daily before meals for a 30-day course. Each capsule contains approximately 20 mg of active peptide. Courses are repeated 2 to 3 times per year per the manufacturer protocol.

Research-chemical Ovagen is sold as 20 mg lyophilized powder vials. Subcutaneous dosing protocols circulating in research-chemical communities use 1 to 5 mg per day over 10 to 20 day cycles. These protocols are extrapolated from generic Khavinson-bioregulator dosing recommendations and are not supported by Ovagen-specific human pharmacokinetic studies.

The course-and-cycle dosing pattern reflects the Khavinson model's claim that bioregulator effects persist between cycles through induced gene-expression changes. Independent confirmation of cycle-spacing optimization for Ovagen specifically is not available.

The compound's small molecular weight and lack of published pharmacokinetic data mean that dosing recommendations cannot be evaluated against established absorption, distribution, metabolism, or elimination parameters in humans.

The Khavinson bioregulator class has a notably benign published adverse-event profile. The Russian manufacturer documentation for Ovagen lists individual intolerance to components, pregnancy, and lactation as the only contraindications. No serious adverse events have been formally reported in Russian-language clinical publications.

This is consistent with the chemical structure. Glutamic acid, aspartic acid, and leucine are common amino acids present in dietary protein. Tripeptide doses at the milligram level fall within or below normal dietary peptide exposure ranges. Acute toxicity from the constituent amino acids is mechanistically implausible.

The relevant safety question is not acute toxicity but chronic effects on liver and GI gene expression. Long-term human safety data with controlled endpoints does not exist for Ovagen. The Khavinson group reports cumulative safety experience from decades of Russian clinical use, but this is not equivalent to a structured long-term safety database with pre-specified hepatic and GI monitoring.

Theoretical concerns flagged in Western reviews of the bioregulator literature include:

• Sustained gene-expression modulation in proliferative liver and GI tissue carries a hypothetical concern about altered cell-cycle regulation. The bioregulator literature claims geroprotective rather than oncogenic effects, but the underlying studies have not been independently replicated to a standard that resolves the concern definitively.
• Drug-drug interaction potential with hepatically metabolized medications. If Ovagen genuinely modulates cytochrome P450 expression as claimed, this would have clinical relevance for patients on cytochrome-metabolized drugs. The magnitude of any such interaction has not been studied in controlled human trials.
• Effects in patients with established liver disease, cirrhosis, or active viral hepatitis have not been characterized.

Within the Khavinson system, Ovagen is positioned as the initial-phase Cytogen for hepatic and gastrointestinal bioregulation, often followed by Svetinorm as the Cytomax for extended support. The Cytogen-first-then-Cytomax sequence is standard Khavinson protocol.

For comprehensive digestive system protocols, Ovagen is combined with Pancragen (pancreatic Cytogen) and Suprefort (pancreatic Cytomax). For broader detoxification and metabolic stacks, Ovagen is combined with Livagen, which targets liver and immune-system function through a different tripeptide sequence (Lys-Glu-Asp-Ala).

For geroprotective stacks, Ovagen is one component of multi-organ protocols alongside Epitalon (pineal), Cerluten (brain), and Vesilute (bladder). No combined-stack human trial has been published.

For external comparators, the closest pharmaceutical categories by claimed effect are hepatoprotective agents such as silymarin (milk thistle extract), ursodeoxycholic acid (UDCA), and N-acetylcysteine (NAC). These have substantially larger Western evidence bases for specific clinical indications. Ovagen is not a substitute for any of them, and decisions about liver-supportive interventions in clinically significant hepatic disease should not rest on the Khavinson bioregulator literature alone.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.